Featured News
February 12, 2025
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
February 05, 2025
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Our Commitment to Responsibility
Corporate responsibility is inherent in our mission as an organization that actively works to support people living with complex and difficult-to-treat psychiatric and neurological disorders and to help break down barriers that prevent people from accessing care. As we do this important work, we strive to manage our business in a manner that promotes transparent governance and strong ethics; maintains extensive stakeholder engagement; and helps us grow our organization strategically, sustainably and responsibly. Our most recent Corporate Responsibility Report expounds on these efforts
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Caregiver Spotlight: Monica Gow
Hear from Monica about lessons learned and the impact of her work as an advocate.
Recognizing Women & Girls in Science
Anh Hoang shares her story in celebration of International Day of Women & Girls in Science
Celebrating our Trailblazer
We're proud to share that our Chief Medical Officer, Craig Hopkinson, was named to the 2024 PharmaVoice 100.
Media Resources
Company Description
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Follow us on our social channels
